Aura cuts 20% workforce, refocuses on ocular oncology; Q2 cash $323.8M

Aura Biosciences, Inc.

Q2 2026 cash and equivalents $323.8M; R&D expense $30.7M (up from $22.9M YoY).
Phase 3 CoMpass fully enrolled (108 patients); topline data expected 2H 2027.
Workforce reduction ~20% with $2.9-3.2M estimated costs; NMIBC program deprioritized.
CFO Tony Gibney departs Sept 1, 2026; Amy Elazzouzi named interim principal financial officer.
Susan Abu-Absi appointed COO; base salary $520K and equity award ~400K shares.

item 2.02 item 2.05 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.